For informational purposes only — not investment advice

← Back to signals

VTRS

LONG

VIATRIS INC

Research: Finviz ↗·Perplexity ↗

Funds
3
Score
3.13
vs SPY
-0.6%
Stock return (since Q-end)
+1.5%
SPY return (since Q-end)
+2.1%
Current price
$16.12
Days to cover (short int.)
4.8d-3.2%
as of 2026-07-31

News Summary

Neutral

Viatris delivered a strong Q2 2026 earnings beat with revenue of $3.76B (+5% YoY) and adjusted EPS of $0.69 (+11%), prompting management to raise full-year 2026 guidance across adjusted EBITDA and EPS. However, sentiment has shifted cautious post-rally with analyst downgrades citing H2 headwinds from supply disruptions and competitive pressures, alongside a CFO transition and declining Effexor sales.

Red flags

  • CFO departure (Mistras) with interim replacement (Campbell) suggests potential internal instability during critical execution period
  • Flagged H2 2026 headwinds from supply disruptions and competitive pressures despite guidance raise
  • Declining Effexor sales cited as concern amid analyst downgrades after strong stock rally
  • Analyst sentiment shifted negative in June 2026 with 'Time To Be More Careful' downgrade after 16-month run, suggesting limited upside momentum

Funds Buying (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Glenview CapitalLarry Robbins9.9M+791K$157M3.1%+9%Existing
Greenlight CapitalDavid Einhorn2.8M+956K$44M1.1%+53%Existing
Point72Steve Cohen563K+563K$9M<0.1%NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.

Portfolio Context

Where VTRS ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.

Glenview Capital

position #11 of this fund's book

  1. 8META PLATFORMS INC$201M
  2. 9ADVANCED MICRO DEVICES INC$173M
  3. 10TEVA PHARMACEUTICAL INDS LTD$172M
  4. 11VIATRIS INC$157M
  5. 12UBER TECHNOLOGIES INC$129M
  6. 13CENTENE CORP DEL$121M
  7. 14BUTTERFLY NETWORK INC$121M
Greenlight Capital

position #33 of this fund's book

  1. 30DECKERS OUTDOOR CORP$50M
  2. 31SPECTRUM BRANDS HOLDINGS INC$48M
  3. 32CNH INDL N V$47M
  4. 33VIATRIS INC$44M
  5. 34PARAMOUNT SKYDANCE CORP$39M
  6. 35PVH CORPORATION$39M
  7. 36COMCAST CORP NEW$33M

Values are quarter-end position sizes. Shown only for funds where VTRS ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
DAVIS SELECTED ADVISERSSC 13G/A75.2M6.5%2026-08-12
FMR LLCSC 13G96.4M8.3%2026-08-06
DAVIS SELECTED ADVISERSSC 13G/A78.2M6.8%2026-05-05
Vanguard Capital ManagementSC 13G84.8M7.4%2026-04-30

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.